Bhutan vs Sudan: Average cost of drugs for extensively drug-resistant tuberculosis
Bhutan
2,259 constant 2022 US$
in 2024
Sudan
1,962 constant 2022 US$
in 2023
Bhutan rank
23rd
Sudan rank
26th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bhutan
- Sudan
How they compare
Bhutan currently reports 2,259 constant 2022 US$ against 1,962 constant 2022 US$ in Sudan, a difference of 297 constant 2022 US$.
That makes Bhutan's figure about 1.2 times Sudan's.
Across all 5 years both countries report, Bhutan has been ahead every year.
Bhutan ranks 23rd and Sudan ranks 26th of 56 countries.
Bhutan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,951 constant 2022 US$ | 830 constant 2022 US$ | 2,121 constant 2022 US$ | Bhutan |
| 2020s | 2,259 constant 2022 US$ | 1,672 constant 2022 US$ | 587.5 constant 2022 US$ | Bhutan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bhutan or Sudan?
- Bhutan, at 2,259 constant 2022 US$ against 1,962 constant 2022 US$ in Sudan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bhutan and Sudan?
- 297 constant 2022 US$, with Bhutan ahead.
- How many years of comparable data are there for Bhutan and Sudan?
- 5 years are reported by both, from 2019 to 2023.
- How do Bhutan and Sudan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bhutan ranks 23rd and Sudan ranks 26th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.